US Biotech Sector Nears Commercialization Inflection Point on Key FDA ApprovalsGlobal Report·19 hours agoCRSP+0.19%GENB-0.46%
Disaggregating the Market: Niche Aggregators, Platform Dependencies, and Physical RealityGlobal Report·1 day ago, 04:12 AMODD-11.89%TEX-5.96%
Gene Editing's 2026 Reality Check: Billion-Dollar Bets and the AI HorizonGlobal Report·Jul 22 at 04:17 AMVRTX-1.44%CRSP+0.19%
The Silent Rotation: Inside the Moves of 10 Niche Tech and Defense PlayersGlobal Report·Jul 21 at 04:12 AMTWLO-3.13%KTOS-9.79%
The Great Biotech Reckoning: When AI and Gene Editing Meet Wall Street's Patience in 2026Global Report·Jul 19 at 04:13 AMAMGN-1.39%CRSP+0.19%
M&A, AI Drug Discovery, and Late-Stage Clinical Readouts Define US Biotech Q2 TrajectoryGlobal Report·Jul 18 at 04:13 AMAMGN-1.39%CRSP+0.19%
10 Health Care Stocks With Whale Alerts In Today’s Sessionbenzinga_article·Jul 1 at 12:35 PMCRSP+0.19%PURR-3.08%
HCA Healthcare says NEJM study shows CRISPR therapy exa-cel hits 12-month endpoints in children 5-11 with sickle cell, beta thalassemiaPUBT·Jun 29 at 07:30 AMHCA-2.39%CRSP+0.19%
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data CatalystsTip Ranks·Jun 24 at 08:15 AMCRSP+0.19%
Why CRISPR Therapeutics stock has been on a roller-coaster ride this yearMSN·Jun 18 at 09:13 AMCRSP+0.19%
Divergent Signals in an Unclassified Cohort: Cross-Border Catalysts and Downside Risks Across 42 EquitiesGlobal Report·Jun 18 at 08:18 AMHNST-2.09%FRO+0.90%
Biotech Sector Sees Crucial Clinical Readouts as Three Firms Advance Pipeline CommercializationGlobal Report·Jun 18 at 04:15 AMCRSP+0.19%RVMD-1.60%
CRISPR Therapeutics (CRSP) Stock Valuation Check After Recent Pullback And Conflicting DCF And P/B SignalsSimplywall·Jun 13 at 04:33 AMCRSP+0.19%
CRISPR Therapeutics AG Stock 12‑Month Price Target Cut to $81.1, Implies 64% UpsideTradingView·Jun 11 at 02:20 AMCRSP+0.19%
